Liquidia to Present at the Jefferies Virtual Healthcare Conference
Rhea-AI Summary
Liquidia Technologies (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company, announced that CEO Neal Fowler will present an overview at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 10:30 AM ET. The event will be accessible via a live audio webcast, available on the company’s website and archived for 90 days. Liquidia focuses on developing novel products using its proprietary PRINT® technology, aiming to enhance therapy safety and efficacy. Notable product candidates include LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, LQDA gained 4.64%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
RESEARCH TRIANGLE PARK, N.C., May 27, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 10:30am Eastern time.
A link to the live audio webcast and replay of the presentation will be available on the Events & Presentations page of the Company’s corporate website, and will be archived for a minimum of 90 days.
About Liquidia
Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.
Contact Information
Investor Relations:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
FAQ
What will Liquidia Technologies present at the Jefferies Virtual Healthcare Conference?
When is Liquidia's presentation scheduled at the Jefferies Virtual Healthcare Conference?
Where can I find the live audio webcast of Liquidia's conference presentation?
What is Liquidia Technologies focusing on with its PRINT technology?
What are the key product candidates of Liquidia Technologies?
